Search results for "liver neoplasm"

showing 10 items of 740 documents

LI-RADS: Diagnostic Performance of Hepatobiliary Phase Hypointensity and Major Imaging Features of LR-3 and LR-4 Lesions Measuring 10-19 mm With Arte…

2019

OBJECTIVE. The purpose of this study was to determine the diagnostic performance of hepatobiliary phase hypointensity and Liver Imaging Reporting and Data System (LI-RADS) major imaging features in the diagnosis of hepatocellular carcinoma (HCC) in hepatic lesions with arterial phase hyperenhancement (APHE) measuring 10-19 mm in patients at high risk of HCC. MATERIALS AND METHODS. A composite reference standard of pathologic analysis and imaging follow-up was used. The diagnostic performance (sensitivity and specificity) of hepatobiliary phase hypointensity and LI-RADS major imaging features other than APHE for the diagnosis of HCC was assessed and compared by means of a logistic regression…

AdultGadolinium DTPAMaleGadoxetic acidCirrhosisCarcinoma HepatocellularContrast MediaspecificityliverSensitivity and Specificity030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinemedicineHumansRadiology Nuclear Medicine and imagingIn patientLiver imagingAgedRetrospective StudiesAged 80 and overbusiness.industryLiver NeoplasmsMean ageGeneral Medicinehepatocellular carcinomaMiddle Agedmedicine.diseasesensitivityMagnetic Resonance Imaginggadoxetate disodiumgadoxetic acid030220 oncology & carcinogenesisHepatocellular carcinomaHepatobiliary phaseFemaleNuclear medicinebusinessArterial phasemedicine.drugMRIcirrhosi
researchProduct

Enhancement pattern of hepatocellular adenoma (HCA) on MR imaging performed with Gd-EOB-DTPA versus other Gd-based contrast agents (GBCAs): An intrai…

2019

Purpose: To conduct an intraindividual comparison of the enhancement pattern of hepatocellular adenoma (HCA) on dynamic MRI study obtained following the injection of Gadoxetic acid (Gd-EOB-DTPA) and other gadolinium-based contrast agents (GBCAs).Method: This is a retrospective, Institutional Review Board-approved study conducted in a single institution. A search of medical records between 2008 and 2017 revealed 17 patients (all females) with at least one pathologically-proven HCA who underwent liver MRI with Gd-EOB-DTPA and another GBCA within 1 year. Enhancement of each lesion on hepatic arterial (HAP), portal venous (PVP), 2 min and 4-5 minutes phases was subjectively evaluated by two abd…

AdultGadolinium DTPAMaleGadoxetic acidGadoliniumPopulationchemistry.chemical_elementContrast Media030218 nuclear medicine & medical imagingAdenoma Liver CellLesion03 medical and health sciences0302 clinical medicineMcNemar's testHepatic ArterymedicineHumansRadiology Nuclear Medicine and imagingeducationAgedRetrospective Studieseducation.field_of_studymedicine.diagnostic_testbusiness.industryPortal VeinLiver NeoplasmsMagnetic resonance imagingGeneral MedicineHepatocellular adenomaMiddle Agedmedicine.diseaseMagnetic Resonance Imagingchemistry030220 oncology & carcinogenesisDynamic contrast-enhanced MRIFemalemedicine.symptomLiver Contrast media Hepatocellular adenoma Magnetic resonance imagingbusinessNuclear medicineSettore MED/36 - Diagnostica Per Immagini E Radioterapiamedicine.drug
researchProduct

Solitary necrotic nodules of the liver: cross-sectional imaging findings and follow-up in nine patients.

2008

OBJECTIVE. The purpose of our study was to retrospectively evaluate the sonographic, CT, and MRI findings (number, diameter, lobar location, depth from the hepatic capsule, and appearance of lesions) in a series of nine patients with pathologically proven solitary necrotic nodules of the liver and the natural evolution at follow-up in four of the nine patients.CONCLUSION. Solitary necrotic nodules are usually small, solitary lesions, mainly located under the liver capsule of the right lobe. They are hypoechoic on sonography, hypoattenuating on CT, have low signal intensity on both T1- and T2-weighted MRI with lack of enhancement after IV contrast administration, and at follow-up have a tend…

AdultGadolinium DTPAMalemedicine.medical_specialtyIohexolIronContrast MediaCross-sectional imagingNecrosisImage Interpretation Computer-AssistedmedicineHumansRadiology Nuclear Medicine and imagingLiver neoplasmMagnetite NanoparticlesAgedRetrospective StudiesFibrous capsule of Glissonmedicine.diagnostic_testbusiness.industryHepatic capsuleLiver NeoplasmsMagnetic resonance imagingDextransOxidesUltrasonography DopplerGeneral MedicineMiddle Agedmedicine.diseaseMagnetic Resonance ImagingLobeFerrosoferric Oxideliver metastases; liver neoplasm; solitary necrotic nodulesmedicine.anatomical_structureLiverFemaleRadiologyTomographyNuclear medicinebusinessTomography Spiral ComputedCalcificationFollow-Up StudiesAJR. American journal of roentgenology
researchProduct

Focal nodular hyperplasia: typical and atypical MRI findings with emphasis on the use of contrast media

2007

Focal nodular hyperplasia is a benign hypervascular hepatic tumour, frequently detected in asymptomatic patients undergoing imaging studies for unrelated reasons. Magnetic resonance imaging (MRI) generally allows a confident differential diagnosis with other hypervascular liver lesions, either benign or malignant. In addition, due to the recent development of hepatospecific MRI contrast agents, MRI concomitantly enables functional and morphological information to be obtained, thus providing important clues for the detection and characterization of focal nodular hyperplasia lesions.

AdultGadolinium DTPAPathologymedicine.medical_specialtymedia_common.quotation_subjectContrast MediaAsymptomaticDiagnosis DifferentialMeglumineGadolinium DTPAOrganometallic CompoundsmedicineHumansContrast (vision)Radiology Nuclear Medicine and imagingmedia_commonmedicine.diagnostic_testbusiness.industryLiver NeoplasmsFocal nodular hyperplasiaMagnetic resonance imagingGeneral MedicineHepatic tumourmedicine.diseaseMagnetic Resonance ImagingFocal Nodular HyperplasiaFemaleRadiologyDifferential diagnosismedicine.symptombusinessIron CompoundsMri findingsClinical Radiology
researchProduct

Expression and prognostic significance of insulin‑like growth factor-2 receptor in human hepatocellular carcinoma and the influence of transarterial …

2019

Hepatocellular carcinoma (HCC) is one of the most common human malignancies, the incidence of which is growing worldwide. The prognosis of HCC is very poor and it is often accompanied by a high rate of recurrence. Conventional chemotherapeutic approaches are largely inefficient. In order to develop novel effective methods for the early detection and prognosis of HCC, novel markers and therapeutic targets are urgently required. The present study focused on the effects of the expression of the tumor suppressor gene insulin‑like growth factor‑2 receptor (IGF2R) on patient survival and tumor recurrence in patients with HCC; this study paid specific attention to the influence of transarterial ch…

AdultLiver CirrhosisMale0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularCirrhosisTumor suppressor geneKaplan-Meier EstimatePolymorphism Single NucleotideDisease-Free SurvivalReceptor IGF Type 203 medical and health sciences0302 clinical medicineInternal medicinemedicineCarcinomaHumansGenetic Predisposition to DiseaseChemoembolization TherapeuticAgedAged 80 and overOncogenebusiness.industryLiver NeoplasmsCase-control studyCancerGeneral MedicineMiddle AgedPrognosismedicine.diseaseMolecular medicinedigestive system diseases030104 developmental biologyOncologyCase-Control Studies030220 oncology & carcinogenesisHepatocellular carcinomaFemaleNeoplasm Recurrence LocalbusinessFollow-Up StudiesOncology Reports
researchProduct

Serum concentration of E-selectin in patients with chronic hepatitis, liver cirrhosis and hepatocellular carcinoma

2000

Objectives: High levels of soluble E-selectin have been reported in acute and chronic inflammatory disorders. Moreover, in some types of tumor elevated values have been found while in other types reduced levels have been reported. Our aims were to determine whether soluble E-selectin levels might be useful in monitoring the progression of chronic liver disease, including hepatocellular carcinoma. Methods: Circulating soluble E-selectin was measured by an enzyme-linked immunosorbent assay in the sera of 18 patients with chronic hepatitis, 44 with liver cirrhosis, and 38 with hepatocellular-carcinoma-associated liver cirrhosis. Immunohistochemical localization of E-selectin was also performed…

AdultLiver CirrhosisMaleCancer Researchmedicine.medical_specialtyPathologyCarcinoma HepatocellularCirrhosismedicine.medical_treatmentChronic liver diseaseInternal medicineE-selectinmedicineHumansAgedHepatitisHematologybiologybusiness.industryLiver NeoplasmsGeneral MedicineHepatitis C ChronicMiddle Agedmedicine.diseaseCytokineOncologyCase-Control StudiesHepatocellular carcinomabiology.proteinImmunohistochemistryFemaleE-SelectinbusinessBiomarkersJournal of Cancer Research and Clinical Oncology
researchProduct

Lysosomal cathepsins B and L and Stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: potential clinical implicati…

1997

The serum levels of lysosomal cathepsin B and L and Stefin A, an intracellular inhibitor of these proteolytic enzymes, were determined in patients with hepatocellular carcinoma (HCC) and/or liver cirrhosis (LC) and correlated with some clinical and biochemical parameters of these diseases. Cathepsin B serum levels were increased in HCC and in LC patients as compared to normal subjects (p < 0.001). However no difference was observed between HCC and LC groups. Interestingly, a significant relationship was evidenced between cathepsin B serum content and the grade of severity of cirrhosis (r = 0.41; p < 0.001). Cathepsin L was significantly elevated only in sera of cancer patients as comp…

AdultLiver CirrhosisMaleCancer Researchmedicine.medical_specialtyPathologyCirrhosisCarcinoma HepatocellularHepatocellular carcinomaoteinase inhibitorCathepsin LLysosomal proteinaseGastroenterologyCathepsin BLiver cirrhosiCathepsin BCathepsin LInternal medicineEndopeptidasesmedicineCarcinomaHumansCystatin AStefin AAgedTumor progression.Aged 80 and overEnzyme PrecursorsbiologyLiver NeoplasmsProteolytic enzymesCancerGeneral MedicineMiddle Agedmedicine.diseaseCathepsinsCystatinsPrCysteine EndopeptidasesOncologyCystatin AHepatocellular carcinomabiology.proteinFemalealpha-FetoproteinsLysosomesOncology
researchProduct

The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases

2005

Knowledge of the current epidemiology of chronic liver disease in Italy is mostly obsolete and fragmentary for the lack of up-to-date consistent data. In 2001, a 6-month prevalence study was undertaken in 79 hospitals to assess the characteristics of chronic liver disease in Italy. Both prevalent and incident cases were enrolled. A total of 9,997 patients were recruited, of whom 939 (9.4%) had normal liver biochemistry, 6,210 (62.1%) had chronic hepatitis, 1,940 (19.4%) had liver cirrhosis, and 341 (3.4%) had hepatocellular carcinoma (HCC). In 567 patients (5.7%) the diagnosis was not established. Hepatitis C virus (HCV) was found in 69.9% of the patients and was the only etiological factor…

AdultLiver CirrhosisMaleHepatitis B virusHBsAgCarcinoma HepatocellularCirrhosisalcohol abuseHepatitis C virusHepacivirusChronic liver diseasemedicine.disease_causeRisk FactorsVirologyPrevalencemedicineHBVHumansAgedbusiness.industryIncidenceLiver DiseasesLiver NeoplasmsHepatitis CMiddle AgedHepatitis BHepatitis Bmedicine.diseaseHepatitis CVirologyAlcoholismInfectious DiseasesItalyHepatocellular carcinomaChronic DiseaseHCVFemaleViral hepatitisbusiness
researchProduct

Frequent Alteration of the Yin Yang 1/Raf-1 Kinase Inhibitory Protein Ratio in Hepatocellular Carcinoma

2011

The transcription factor Yin Yang 1 (YY1) can favor several aspects of tumorigenesis. In turn, Raf-1 Kinase Inhibitor Protein (RKIP) inhibits the oncogenic activities of MAPK and NF-κB pathways and promotes drug-induced apoptosis. Mutual influences between YY1 and RKIP may exist, and there are already separate evidences that relevant increases in YY1 and reductions in RKIP occur in hepatocellular carcinoma (HCC). However, the levels of the two factors have never been concomitantly examined in HCC. We evaluated by RT-PCR the mRNA levels of YY1, YY1AP, RKIP, and survivin in 35 clinical HCCs (91% HCV-related), in their adjacent cirrhotic tissues and in 6 healthy livers. Immunohistochemical ana…

AdultLiver CirrhosisMaleMAPK/ERK pathwayCarcinoma HepatocellularSettore MED/09 - Medicina InternaSurvivinCell Cycle ProteinsPhosphatidylethanolamine Binding ProteinSettore MED/08 - Anatomia PatologicaBiologymedicine.disease_causeBiochemistryInhibitor of Apoptosis ProteinsSurvivinGeneticsmedicineHumansRNA MessengerHepatocellular carcinomaYY1RKIPMolecular BiologyTranscription factorYY1 Transcription FactorAgedAged 80 and overSettore MED/12 - GastroenterologiaHepatocellular carcinoma Yin Yang 1 Raf-1 Kinase Inhibitor Protein Yin Yang 1-associated proteinKinaseYY1Liver NeoplasmsNuclear ProteinsMiddle AgedHCCSmedicine.diseaseGene Expression Regulation NeoplasticLiverHepatocellular carcinomaembryonic structuresSettore BIO/14 - FarmacologiaCancer researchMolecular MedicineFemaleSettore SECS-S/01 - StatisticaCarcinogenesisTranscription FactorsBiotechnologyOMICS: A Journal of Integrative Biology
researchProduct

Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis

2009

GOALS AND BACKGROUND: The multikinase inhibitor sorafenib provides survival benefit for patients with advanced hepatocellular carcinoma (HCC) and liver cirrhosis (LCI) Child-Pugh A. We report our experiences with sorafenib in advanced HCC, particularly in patients with LCI Child-Pugh B/C, where only limited data are available in regard to safety and efficacy of sorafenib. METHODS: Thirty-four patients with advanced HCC were treated with sorafenib regardless of liver function and prior anticancer therapy. Adverse events (AEs) were graded using Common Toxicity Criteria version 3.0, tumor response was assessed according to Response Evaluation Criteria in Solid Tumors. RESULTS: Fifteen patients…

AdultLiver CirrhosisMaleNiacinamideSorafenibmedicine.medical_specialtyCarcinoma HepatocellularTime FactorsCirrhosisPyridinesAntineoplastic AgentsKaplan-Meier EstimateRisk AssessmentSeverity of Illness IndexGastroenterologyInternal medicinemedicineCarcinomaHumansProspective StudiesProtein Kinase InhibitorsAgedAged 80 and overbusiness.industryPatient SelectionPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsGastroenterologyCancerMiddle AgedSorafenibmedicine.diseasedigestive system diseasesSurgeryTreatment OutcomeResponse Evaluation Criteria in Solid TumorsHepatocellular carcinomaConcomitantFemaleLiver functionbusinessmedicine.drugJournal of Clinical Gastroenterology
researchProduct